Market research
BALAXI.NSE Balaxi Pharmaceuticals Limited
NSE INR Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- 92.69
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.7
Community
Investor discussion
1 comment
Sign in to join the BALAXI.NSE discussion.
5 years, 4 months ago
Balaxi Pharmaceuticals Limited is currently in a long term downtrend where the price is trading 6.5% below its 200 day moving average.
From a valuation standpoint, the stock is 5.1% cheaper than other stocks from the Other sector with a price to sales ratio of 2.2.
Balaxi Pharmaceuticals Limited's total revenue rose by 402.1% to $660M since the same quarter in the previous year.
Its net income has increased by 343.0% to $110M since the same quarter in the previous year.
Finally, its free cash flow grew by 120.3% to $17M since the same quarter in the previous year.
Based on the above factors, Balaxi Pharmaceuticals Limited gets an overall score of 4/5.